Cell Harvesting Systems Market

Cell Harvesting Systems Market Size (2023 to 2028)

The size of the global cell harvesting systems market was around USD 4.91 billion in 2023. It is expected to grow at a CAGR of 13.7% to reach USD 9.33 billion by 2028.

The cell harvesting technique is expected to lead the biopharmaceutical market in the future, mainly due to its broad scope of diseases like skin regeneration after burns, cancer, etc.

MARKET DRIVERS:

Factors such as increasing demand for stem cell-based therapy and rising investment in clinical research are primarily accelerating the growth of the cell harvesting systems market.

The growing aging population and an increase in the number of cardiovascular cases are other significant factors propelling the market. The rising transplantation rate and the increasing demand for stem cell banking also play a responsible role in the increasing requirement of harvesting across the globe. Overall growth in the biotechnology industry will have a positive impact on the cell harvesting market.

Increased bone marrow transplantation procedures due to the high prevalence of blood cancer and anemia drive the cell harvesting systems market. The demand for stem cell-based therapy is expected to grow as the population ages, and the prevalence of chronic diseases such as cardiovascular disease rises are propelling the market demand. Cell harvesting systems aid in scar regeneration by improving proper pigmentation, which encourages businesses to invest in ongoing technological advancements in cell isolation techniques and downstream purification processes. Due to the high concentration of bone marrow stem cell harvesting centers and registries and qualified doctors for harvesting stem cells, the demand for cell harvesting systems is growing at a higher rate. 

The increasing investment in regenerative medicine and cell-based science and the growth of the biotechnology and pharmaceutical industries are all pushing the cell harvesting market forward. Many companies are working on myocardial tissue regeneration through the infusion of cell grafts made up of adult stem cells from patients to create regenerative medicines. Various technological advancements are expected to fuel new and better technologies with improved performance, propelling the cell harvesting systems market during the forecast period. Furthermore, rising investment in logistic facilities, expanding the bone marrow transplant registry for heart and neuronal disorders, and rising per capita healthcare expenditure are all factors to consider as opportunities for market growth.

MARKET RESTRAINTS:

Immune rejection and a lack of reimbursement policies are expected to stymie the global cell harvesting systems market. However, ethical concerns about embryonic stem cells and unapproved stem cell therapy offered by healthcare providers in unregulated regions like Latin America and the Asia Pacific are expected to restrain the market growth over the forecast period. The ethical issues surrounding stem cell therapies and the high cost of the therapy could limit the market's growth during the forecast period.

The global cell harvesting systems market is further restricted to the ethical issues that have risen along with the stem cell market's growth. Unapproved stem-cell therapy prevalent in Latin America and Asia Pacific region is also a significant reason that might restrict the growth. Countries with no proper technology will restrain themselves from using this technique, thus limiting the growth in that region.

The high cost of inconvenient therapy, viable cell density, and problems during cell harvesting, an inadequate number of HSCs (Hematopoietic stem cells) cells for transplantation, and the identification of stem cells in adult tissues are all major challenges to the cell harvesting systems sector.

COVID-19 impact on the global cell harvesting systems market:

COVID-19 has had a lot of effects on the market. Scientists are trying to find a cure for COVID-19 using advanced harvesting. Governments have now seen the potential of stem cell harvesting in treating diabetes, cardiovascular diseases, etc. Thus, more funds are being allotted for further research and development. Policies are also being regulated for private firms in the field of stem cell marketing. The benefit harvesting in treating diabetes is very beneficial for patients as the covid19 affects people with diabetes and cardiovascular problems. By the end of COVID-19, we may see significant development in this market.

REPORT COVERAGE:

This research report on the global cell harvesting systems market has been segmented and sub-segmented into the following categories.

Cell Harvesting Systems Market– By Application:

• Bone Marrow
• Umbilical Cord
• Adipose Tissue
• Peripheral Blood

Based on the application, the application segment is dominated by Peripheral Blood and is forecast to maintain its dominance in the years to come. Peripheral blood had the largest market segment in 2019 and is expected to grow at a promising rate during the forecast period. It can be attributed to the high use of peripheral blood in stem cell transplants and the growing use of peripheral blood in stem cell research. The governments are now collaborating to expand the research in this field due to good past results.

Adipose tissue is expected to witness the highest growth rate during the forecast period but has a fourth place in market share. The growth is fast due to the retrieval of many stem cells from liposuction and their potential use in regenerative medicine. The increase in regenerative medicine will drive growth further.

The Bone marrow segment was the second-largest in 2022 and is expected to grow at a healthy rate. The benefits of this are huge, and the government's support drives growth at a swift pace.

The umbilical cord is expected to grow at the second-fastest rate. The growth is owing to its increasing use in transplantation and potential use in other therapies.

Cell Harvesting Systems Market – By End User:

• Academic Institutes
• Hospitals
• Diagnostic Labs
• Research Centers

Based on end-user, because a significant part of cell harvesting for stem cell regeneration is done in hospitals, hospitals lead the end-user segment of the market. They are expected to retain their top position in the forecast period. The growth of stem cell harvesting in academic institutes is also estimated to be fuelled by the rise in cell harvesting research.

Hospitals held the largest share and are expected to continue the dominance over the forecast period, as most stem cell harvesting for transplantation & research is undertaken in hospitals. Hospitals have massive funding and, thus, can carry out more research than other users.

Academic institutes and Research and Development centers are expected to witness the fastest growth due to growing investment in research by universities and biopharmaceutical companies. The rising demand for regenerative medicine and stem cell-based therapies is further expected to contribute toward the development.

The diagnostic labs segment is estimated to have the smallest market share and is expected to have less growth than others. Access to fewer funds is restricting the development of this sub-segment.

Cell Harvesting Systems Market – By Technique:

• Blastomere Extraction
• Altered Nuclear Transfer

Based on the technique, the Blastmore extraction technique is one possible way around the ethical concerns that result from the destruction of an embryo. It has driven the growth of technology and is expected to lead from other techniques.

Altered nuclear transfer (ANT) may make it feasible for stem cells to be removed from embryos without destroying the embryo itself in the process. It could offer a way out of the current ethical dilemmas surrounding embryonic stem cell research and drive the growth of this market.

Cell Harvesting Systems Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Given the higher rate of stem cell research and transplantation, North America and Europe dominate the market. An increase in cancer prevalence and the rise in the aging population also propel market growth in these areas. North America has dominated this market over the years. Around 55% of clinical trials in the world are done in the North American region. Advanced medical research facilities have contributed to the growth. Stem cell transplantation is also done majorly in North America and driving the growth.

Europe accounted for the second-largest market share in 2022 and is expected to register the highest growth. Growth in healthcare facilities with governments investing a lot of money is the primary reason for the development.

The Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to the rising incidence of chronic diseases and increasing demand for stem cell transplantation and stem cell-based therapy. Japan and China are the biggest markets for harvesting systems in the Asia Pacific.

KEY MARKET PLAYERS:

Some of the noteworthy companies leading the global cell harvesting systems market profiled in this report are Avita Medical, Tomtec, Terumo Corporation, Perkin Elmer, Inc., Argos Technologies, Inc., Bertin Technologies, Arthrex, Inc., Brand GmBh + CO KG, Thomas Scientific and Tereflex, Inc.

RECENT MARKET HAPPENINGS:

• Jasper Therapeutics, Inc. announced its launch in December 2019 with a total Series A funding of US$ 35 million. JSP191, the company's lead product candidate, is being developed to substitute for the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic cell transplantation. 
• OrganaBio released the HematoPAC HSC-CB CD34 hematopoietic stem cell (HSC) product in March 2021, which aids in supporting HSC-based allogeneic cell therapies.
• Cipla and Stempeutics collaborated to deliver Stempucel, a cell therapy to treat critical limb ischemia, in August 2020. The medication is used to treat CLI caused by Buerger's Disease and Atherosclerotic Peripheral Artery Disease. It is India's first allogeneic cell therapy device to be licensed for commercial use and the world's first stem cell product for CLI care.
• Terumo BCT and Cognate Bioservices, a service contract company, developed a strategic partnership in September 2016 to improve immunotherapy and other related products and expand the use of quantum systems in cell therapy manufacturing.